Literature DB >> 28285359

Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1.

Jun Wang1,2, Yan Cheng1, Xiaoran Yin1, Jie Wu1, Yumei Luo1, Jing Wu1, Jia Di1, Dong Liu1, Yahui Huang2, Rong Zhang1, Jun Zhang3.   

Abstract

Esophageal adenocarcinoma (EAC) is one of the most common malignancies in the world which is associated the increased prevalence of obesity. In the context of obesity, leptin can directly contribute to progression of EAC. Adiponectin inhibits leptin-induced oncogenic signaling in EAC cells. However, the exact molecular mechanisms linking obesity, adipokines, and EAC remain far from completely understood. In the present study, we tested the role of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) in adiponectin-induced protective effects against leptin-induced EAC cell proliferation. We found that globular adiponectin (gAD) significantly inhibited leptin-induced increase of cell proliferation and decrease of apoptosis in OE 19 cells. Moreover, leptin-induced increase of UHRF1 expression was suppressed by gAD. Compared with normal controls, UHRF1 expression was markedly increased in EAC tissues and cell lines. Silence of UHRF1 increased the expression of cleaved caspase 3 and 9 and Bax, reduced the expression of Bcl-2, promoted apoptosis, and inhibited cell proliferation in OE 19 cells. Overexpression of UHRF1 significantly blocked gAD-induced decrease of cell proliferation and increase of apoptosis in leptin-treated cells. Silence of adiponectin receptor 1/2 (AdipoR1/2) could inhibit gAD-induced decrease of cell proliferation and increase of apoptosis in leptin-treated cells. Silence of AdipoR2, but not AdipoR1, suppressed gAD-induced decrease of UHRF1 expression in leptin-treated cells. The results indicated that gAD inhibited the prooncogenic effects of leptin via AdipoR2-mediated suppression of UHRF1. Our study provides novel insights into the role of UHRF1 in the development of EAC and the mechanism of antitumor effect of gAD.

Entities:  

Keywords:  Adiponectin; Adiponectin receptor; Esophageal adenocarcinoma; Leptin; Ubiquitin-like with PHD and ring finger domains 1

Mesh:

Substances:

Year:  2017        PMID: 28285359     DOI: 10.1007/s11010-017-2980-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.

Authors:  Olivia M Thompson; Shirley A A Beresford; Elizabeth A Kirk; Mary P Bronner; Thomas L Vaughan
Journal:  Obesity (Silver Spring)       Date:  2010-01-28       Impact factor: 5.002

2.  Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece.

Authors:  Eleni Petridou; Christos Mantzoros; Nick Dessypris; Panagiotis Koukoulomatis; Carol Addy; Zannis Voulgaris; George Chrousos; Dimitrios Trichopoulos
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

3.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

5.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

6.  Plasma adiponectin and gastric cancer.

Authors:  Makoto Ishikawa; Joji Kitayama; Shinsuke Kazama; Takeyuki Hiramatsu; Kenji Hatano; Hirokazu Nagawa
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

7.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

8.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression.

Authors:  G M Lord; G Matarese; J K Howard; R J Baker; S R Bloom; R I Lechler
Journal:  Nature       Date:  1998-08-27       Impact factor: 49.962

9.  Prostate cancer cell proliferation is influenced by leptin.

Authors:  Ponnandai Somasundar; Krista A Frankenberry; Heath Skinner; Giridhar Vedula; David W McFadden; Dale Riggs; Barbara Jackson; Reyna Vangilder; Stanley M Hileman; Linda C Vona-Davis
Journal:  J Surg Res       Date:  2004-05-01       Impact factor: 2.192

10.  Adiponectin and leptin receptors expression in Barrett's esophagus and normal squamous epithelium in relation to central obesity status.

Authors:  A Mokrowiecka; M Sokolowska; E Luczak; M Dudojc; J Wieczfinska; D Kacprzak; A Wierzchniewska-Lawska; R Pawliczak; E Malecka-Panas
Journal:  J Physiol Pharmacol       Date:  2013-04       Impact factor: 3.011

View more
  1 in total

Review 1.  Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression.

Authors:  Tsung-Chieh Lin; Kuan-Wei Huang; Chia-Wei Liu; Yu-Chan Chang; Wei-Ming Lin; Tse-Yen Yang; Michael Hsiao
Journal:  Oncotarget       Date:  2018-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.